Status:
COMPLETED
Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies
Lead Sponsor:
Keio University
Conditions:
Acute Myelogenous Leukemia
Acute Lymphoblastic Leukemia
Eligibility:
All Genders
20-55 years
Phase:
PHASE1
PHASE2
Brief Summary
The primary purpose of this study is to evaluate the safety and efficacy of cord blood transplantation for adult patients with hematologic malignancies including refractory acute leukemia. The transpl...
Detailed Description
Although cord blood is considered as an alternative donor source for allogeneic hematopoietic stem cell transplantation, its procedure has yet to be standardized. Recently, a single institute result o...
Eligibility Criteria
Inclusion
- Clinical diagnosis of acute leukemia, chronic myelogenous leukemia, and myelodysplastic syndrome
- Lack of HLA-identical or 1 locus mismatched related donor
- Age over 20, and under 55
- Performance status 0 or 1
- No moderate or sever organ dysfunction (liver, kidney, heart, lungs)
- No anti-HLA antibody
- Informed consent was obtained
Exclusion
- Uncontrollable diabetes
- Uncontrollable hypertension
- Active infection
- TPHA, HBs-Ag, HCV-Ab positive
- HTLV-I, HIV positive
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2011
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT00270881
Start Date
January 1 2006
End Date
January 1 2011
Last Update
April 6 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Keio University School of Medicine
Tokyo, Japan, 160-8582